Zentiva and Euractiv Bring Policymakers Together for Health Policy Conference
Ensuring Fair Access to Medicines for All
PRAGUE and BRUSSELS, May 22, 2025 /PRNewswire/ — Zentiva supported Euractiv's Health Policy Conference in Brussels, where its CEO, Steffen Saltofte, joined senior EU policymakers in the opening panel titled 'The EU Pharmaceutical Legislation – Ensuring Fair Access to Medicines for All.'
Representing Europe's off-patent medicine sector, Steffen Saltofte called for a unified approach to reshape pharmaceutical policy with patients at the centre. He emphasised the need to bring together all healthcare stakeholders — from innovators to the off-patent industry, from regulators to policymakers — to fulfil the promise of health as a fundamental right for all.
'We need sustainable healthcare that is resilient and that people can trust,' said Steffen Saltofte. 'Our EU-based plants delivered throughout COVID and recent shortages — but continued resilience is only possible with a systemic framework that ensures fair and simple rules, predictable pricing, and an aligned policy approach that truly puts patients first. If we want equal access to medicines, we must invest in the system. That means working together to secure medicines for all — across availability, affordability, and accessibility. This demands fair, forward-looking rules and a shared commitment to Europe's healthcare sovereignty. This is not about one part of the system — it's about delivering one healthcare, for all.'
Key topics that Zentiva underlined during the discussion:
Equal Access and Timely Competition Are VitalWe advocate for pharmaceutical reform that guarantees early patient access through fair competition. Extending exclusivity periods could delay the entry of generics and biosimilars, impacting both affordability and availability.
Resilience Starts with Economically Viable EU-Based ManufacturingOur manufacturing sites in Prague and Bucharest maintained continuous supply during recent crises. We call for predictable pricing, investment incentives, and smart procurement rules to secure local production of essential medicines — not just for a few substances, but across the portfolio, ensuring fair access for all who depend on medicines every day.
Policy Alignment and Cross-Sector Cooperation Are EssentialIndustrial, pharmaceutical, and environmental policies must be aligned. Without coordination, new directives — such as the Urban Wastewater Treatment Directive — risk undermining medicine supply and innovation in greener technologies.
A Modern Framework for Sustainable Healthcare Is NeededWe support reforms that accelerate the adoption of digital tools, such as digital leaflets, incentivize value-added medicines, and ensure pricing systems reflect real-world costs and sustainability goals.
Moderated by EURACTIV's Anna Gumbau, the discussion featured Rainer Becker, Director for Medical Products and Innovation at DG SANTE in the European Commission; Stine Bosse, Member of the European Parliament and Vice-Chair of the SANT Committee; and Ondřej Knotek, Member of the European Parliament and of the SANT Committee.
Platforms like the one provided by Euractiv are vital — they bring us together to listen, collaborate, and drive progress. For the benefit of all people who rely on medicines every day. Because health is a right, not a privilege.
About ZentivaZentiva provides health and wellbeing for all generations. We are a European company developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. The company is private equity-owned, delivering sustainable growth, with an ambitious plan for the years to come.
We are a team of more than 5,000 unique talents bonded together by our commitment to ensuring the supply of high-quality, affordable medicines to people who depend on them every day. We want Zentiva to be a great place to work, where everyone feels welcomed and appreciated, and can be their true selves, contributing to the best of their ability.
Our roots reach back more than 500 years to a small pharmacy in Prague that still exists today. We act today for a sustainable tomorrow, so that Zentiva will continue to provide health and wellbeing for all generations for at least another 500 years.
www.zentiva.com
Photo – https://mma.prnewswire.com/media/2694115/Zentiva_Euractiv_panel.jpgLogo – https://mma.prnewswire.com/media/2660891/5333521/Zentiva_Logo.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Biodefense Market worth $1.81 billion by 2030
DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ — The biodefense market is projected to grow from USD 0.89 billion in 2025 to USD 1.81 billion by 2030 at a CAGR of 15.1% during the forecast period according to a new report by MarketsandMarkets™. The biodefense market is driven by increasing bioterrorism, growing geopolitical tensions, biological warfare risks, and advancements in technology. Biodefense encompasses a range of tools and systems designed to detect, prevent, and respond to biological threats, including infectious diseases, bioterrorism, and accidental pathogen releases. These include biosensors, rapid detection platforms, decontamination systems, mobile containment units, and AI-driven surveillance tools. The market for biodefense technology is experiencing strong growth due to increasing global concerns over pandemics, biological warfare, and emerging infectious diseases. Download PDF Brochure: Browse in-depth TOC on 'Biodefense Market' 196 – Tables56 – Figures217 – Pages Biodefense Market Report Scope: Report Coverage Details Market Revenue in 2025 $ 0.89 billion Estimated Value by 2030 $ 1.81 billion Growth Rate Poised to grow at a CAGR of 15.1% Market Size Available for 2020–2030 Forecast Period 2025–2030 Forecast Units Value (USD Million/Billion) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered By Technology, Product, Application and Region Geographies Covered North America, Europe, Asia Pacific, and Rest of World Key Market Challenge Infrastructure constraints in low-resource areas Key Market Opportunities Emergence of AI-powered biosurveillance and predictive analytics Key Market Drivers Rising threat of Bioterrorism Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Hospitals are the initial point of contact for the identification of unusual infections or exposure to biological agents, and hence, they must have sophisticated containment systems, sterilization apparatus, and pathogen detection instruments in real time. With increasing bioterrorism, governments and health agencies are investing heavily in the upgrade of hospital biosafety facilities, such as Class III biological safety cabinets, mobile isolation units, and UV sterilization technology, all of which are becoming essential for modern biodefense infrastructure. These facilities need safe conditions to work with high-risk pathogens, which fuels the demand for low-temperature sterilizers, decontamination chambers, and air purification. The growing incorporation of digital surveillance platforms and smart biodefense technologies in healthcare facilities further solidifies their role in early detection and quick response, making hospitals & medical institutes the largest application segment of the biodefense market. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period due to its significant contributions toward monitoring real-time pathogens, forecasting, and fast decision-making. AI facilitates the convergence and synthesis of large-scale environmental data and enables early threat detection and quick response coordination. Governments and health organizations globally are increasingly using AI platforms to track bio-threats across borders and to automatically report disease transmission for strategic purposes. Additionally, AI technologies are being integrated into biosensor networks, autonomous disinfecting robots, and predictive modeling applications utilized in hospitals, airports, and military bases. The increasing focus on digitally empowered biodefense infrastructure, coupled with significant investments by public and private sectors, is expected to fuel the growth of the AI segment in the global market. Inquiry Before Buying: Asia Pacific is projected to register the highest CAGR during the forecast period. Asia Pacific is projected to register the highest CAGR in the biodefense industry through the forecast period due to increasing investments in public health infrastructure, infectious disease surveillance, and military biosafety capacities. China, India, Japan, and Australia are comprehensively developing their biodefense capabilities. These countries are investing in mobile biosafety laboratories, near-real-time pathogen detection systems, and next-generation decontamination technologies to anticipate future biological threats. Also, the region is experiencing growth in biotechnology R&D, cross-border health security efforts, and government-backed biodefense programs. The growth of local biotech and med-tech firms is also propelling innovation in AI-powered disease monitoring, biosensors, and portable sterilizers for civilian and military applications. The growing population, susceptibility to zoonotic disease, and proactive policy changes are driving significant growth in the regional biodefense market. STERIS (US), ASP International GmbH (a subsidiary of Fortive) (US), Ushio Inc. (Japan), Sotera Health Company (US), and Bioquell, An Ecolab Solution (UK) are the major key players in the biodefense companies. These companies have strong distribution networks across regions like North America, Europe, Asia Pacific, and the Rest of the World. Get 10% Free Customization on this Report: Browse Adjacent Market: Aerospace and Defence Market Research Reports & Consulting Related Reports: Border Security Market by Domain (Land, Maritime, Airborne), Vertical (Military, Homeland Security), System (Surveillance Systems, Detection Systems, Communication Systems, Command and Control Systems), Installation & Region – Global Forecast to 2029 CBRN Defense Market by Type (Chemical, Biological, Radiological, Nuclear, Explosives), Equipment (Protective Wearables, Respiratory Systems, Detection & Monitoring Systems, Decontamination Systems, Simulators, Others), End Use and Region – Global Forecast to 2028 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Web Site: Insight: Source: Logo: View original content:
Malaysian Reserve
9 hours ago
- Malaysian Reserve
PLADUOpro: The World's First Dual Gas Plasma System Revolutionizing Aesthetic Skincare
CORDOVA, Tenn., June 5, 2025 /PRNewswire/ — Aesthetic Management Partners, a leader in regenerative medical aesthetics, is proud to announce the launch of the PLADUOpro– the world's first dual Argon and Nitrogen gas plasma system for skin restoration. The PLADUOpro platform is the evolution of more than 20 years of research to provide next-generation non-surgical skin revitalization. Whether clients seek a quick, no-downtime refresh or a deeper, transformative renewal, PLADUOpro provides tailored solutions for every need. Powered by patented Spin-Shot technology, PLADUOpro ensures unparalleled control and efficacy. This innovation allows practitioners to fine-tune energy delivery with precision, enhancing safety and accelerating outcomes across all skin types. 'We're proud to introduce PLADUOpro to the North American market. Patients want natural-looking results, with little downtime, and the PLADUOpro was built to fit this need. PLADUOpro will change the way we approach aesthetic treatments,' said Erik Dowell, Founder and CEO of Aesthetic Management Partners. 'At SHENB, innovation is at the core of everything we do. PLADUOpro is the result of years of research and development to deliver safe, effective, and unique outcomes for patients,' said Sunny Kang, CEO of SHENB Co. Ltd. 'We are thrilled to collaborate with Aesthetic Management Partners to launch this technology in the North American Market. We look forward to helping patients and clinics together.' About Aesthetic Management PartnersAesthetic Management Partners is a leader in regenerative medical solutions for skin and hair. The company's portfolio includes plant-based patented technology for skin and hair revitalization and is complemented by a portfolio of unique aesthetic energy-based devices. For more information, please contact:Aesthetic Management PartnersMarina Kamenakis, VP
Malaysian Reserve
11 hours ago
- Malaysian Reserve
Pantai Hospital Kuala Lumpur Advances Adult Congenital Heart Care with First Minimally Invasive PDA Device Closure
KUALA LUMPUR, Malaysia, June 6, 2025 /PRNewswire/ — Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone in cardiovascular care with the successful transcatheter device occlusion of a patent ductus arteriosus (PDA) in an adult patient with congenital heart disease — a first for the hospital's Interventional Cardiology Laboratory (ICL). The patient, who was initially referred for open-heart surgery involving PDA ligation and ventricular septal defect (VSD) closure, was carefully evaluated by PHKL's multidisciplinary cardiac team. A detailed transoesophageal echocardiogram (TOE) revealed a single tiny VSD that did not require immediate surgical repair, allowing the team to opt for a less invasive, catheter-based approach. 'This case is a testament to multidisciplinary, patient-centred approach,' said Dr Siti Laura, Consultant Paediatric Cardiothoracic Surgeon at PHKL. 'By opting for a minimally invasive PDA device occlusion, we were able to offer the patient a faster recovery, smaller incision, and significantly reduced scarring.' This successful procedure highlights PHKL's expanding capabilities in adult congenital heart care, a specialised and growing field that requires collaborative planning and tailored interventions. It also reflects the hospital's commitment to delivering innovative, minimally invasive solutions for structural heart conditions in adults — a group often underrepresented in congenital cardiac care Our ability to perform such procedures reflects the hospital's continuous investment in advanced cardiac technology and our commitment to improving outcomes for patients with congenital heart disease,' Dr Siti Laura added. 'We will continue to monitor the patient's condition closely — particularly her VSD — to ensure optimal long-term care. PHKL reinforces its position as a tertiary referral centre and a growing centre of excellence for adult congenital heart disease management in Malaysia. For more information about Paediatric and Congenital Cardiothoracic Services at PHKL, please visit: -END- *** Dr Siti Laura Mazalan, Consultant Paediatric and Congenital Cardiothoracic Surgeon MBBS (University of Malaya, Malaysia), MMed Surg (University Kebangsaan Malaysia, Malaysia), Fellowship in Paediatric Cardiac Surgery (Birmingham Children Hospital, United Kingdom) Dr. Siti Laura is a highly accomplished Paediatric Cardiothoracic Surgeon deeply committed to serving vulnerable in Malaysia. Her medical journey commenced with an MBBS from the University of Malaya in 1998, followed by a Master of Medicine (Surgery) from Universiti Kebangsaan Malaysia in 2004. Beginning her career at Institute Jantung Negara in 2004, she devoted 14 years to the institution as a Consultant Cardiothoracic Surgeon. Motivated by her dedication to enhancing healthcare, she pursued a transformative one-year Fellowship in Paediatric Cardiac Surgery at Birmingham Children's Hospital in 2010. In 2020, Dr. Siti Laura joined Serdang Hospital, where she played a pivotal role in establishing the Paediatric Cardiothoracic service, catering to underprivileged children with congenital heart diseases in the nation. She subsequently became a Consultant Paediatric Cardiothoracic Surgeon at Pantai Hospital Kuala Lumpur. Dr Siti Laura's area of interest includes Neonatal and Paediatric Cardiothoracic Surgery, Adult Congenital Cardiac Surgery, Single Ventricle Heart Surgery, ECMO support (Extracorporeal membrane oxygenation), Slide Tracheoplasty Surgery in neonates and paediatric patients and Cardiac Homograft Banking. Dr Siti Laura's expertise and unwavering dedication continue to make a profound impact on the lives of her patients and the healthcare community. *** About Pantai Hospital Kuala Lumpur For five decades, Pantai Hospital Kuala Lumpur has been the heartbeat of Kuala Lumpur, steadfastly delivering exceptional care to patients from all walks of life. Since its inception in 1974 with just 68 beds and 20 medical specialists, the hospital has grown into a healthcare icon today with 507 beds, over 200 consultants and counting. Our pursuit of quality healthcare, clinical excellence, and cutting-edge technology is underscored by our service quality and dedication towards clinical research. This has earned us accreditations from the Malaysian Society for Quality in Health (MSQH) and the Joint Commission International (JCI). Additionally, we hold certification as a Baby-Friendly Hospital and is a preferred hospital in Malaysia by the World Health Organization (WHO). As we celebrate our 50th anniversary, Pantai Hospital Kuala Lumpur looks to the future, unwaveringly committed to continuing its legacy of excellence with world-class healthcare services and innovative treatments for generations to come. Learn more at For more information, please contact:Callie Phin, Pantai Hospital Kuala LumpurEmail: Tel No.: 014-686 7066 For media enquiry:Natasha Loo, PR Lab ConsultancyEmail: tasha@ Tel No.: 010-231 0110 Lim Joe Ee, PR Lab ConsultancyEmail: Tel No.: 012-635 9839 Ally Chai, PR Lab ConsultancyEmail: ally@ Tel No.: 016-232 7625
